Possible therapeutic effect of magnesium sulfate in pre-eclampsia by the down-regulation of placental tumor necrosis factor-alpha secretion

European Cytokine Network

Volumn 21, Issue 1, 2010, Pages 58-64

  Amash, Alaa ^a,b   Weintraub, Adi Y ^b   Sheiner, Eyal ^b   Zeadna, Atef ^b   Huleihel, Mahmoud ^a,b   Holcberg, Gershon ^b  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Magnesium sulfate; Placental perfusion; Pre eclampsia; Tumor necrosis factor alpha

Indexed keywords

MAGNESIUM SULFATE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FEMALE; FETUS CIRCULATION; HUMAN; MATERNAL BLOOD; PLACENTA; PLACENTA PERFUSION; PREECLAMPSIA;

ADULT; DOWN-REGULATION; FEMALE; HUMANS; MAGNESIUM SULFATE; MATERNAL-FETAL EXCHANGE; PERFUSION; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77149123979     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: 10.1684/ecn.2009.0178     Document Type: Article

References (35)

1. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33. Obstet Gynecol 2002; 99: 159-67.
2. Lain KY, Roberts JM. Contemporary concepts of the pathogenesis and management of preeclampsia. JAMA 2002; 287: 3183-6.
3. Sibai BM, Caritis S, Hauth J. What we have learned about preeclampsia. Semin Perinatol 2003; 27: 239-46.
4. Kharfi A, Giguère Y, Sapin V, Massé J, Dastugue B, Forest JC. Trophoblastic remodeling in normal and preeclamptic pregnancies: implication of cytokines. Clin Biochem 2003; 36: 323-31.
5. Page NM. The endocrinology of pre-eclampsia. Clin Endocrinol (Oxf) 2002; 57: 413-23.
6. LaMarca BD, Ryan MJ, Gilbert JS, Murphy SR, Granger JP. Inflammatory cytokines in the pathophysiology of hypertension during preeclampsia. Curr Hypertens Rep 2007; 9: 480-5.
7. Rusterholz C, Hahn S, Holzgreve W. Role of placentally produced inflammatory and regulatory cytokines in pregnancy and the etiology of preeclampsia. Semin Immunopathol 2007; 29: 151-62.
8. Brewster JA, Orsi NM, Gopichandran N, McShane P, Ekbote UV, Walker JJ. Gestational effects on host inflammatory response in normal and pre-eclamptic pregnancies. Eur J Obstet Gynecol Reprod Biol 2008; 140: 21-6.
9. Haider S, Knöfler M. Human Tumour Necrosis Factor: Physiological and Pathological Roles in Placenta and Endometrium. Placenta 2008; doi:10.1016/j.placenta.2008.10.012.
10. Conrad KP, Benyo DF. Placental cytokines and the pathogenesis of preeclampsia. Am J Reprod Immunol 1997; 37: 240-9.
11. Conrad KP, Miles TM, Benyo DF. Circulating levels of immunoreactive cytokines in women with preeclampsia. Am J Reprod Immunol 1998; 40: 102-11.
12. Wang Y, Walsh SW. TNF alpha concentrations and mRNA expression are increased in preeclamptic placentas. J Reprod Immunol 1996; 32: 157-69.
13. Benyo DF, Smarason A, Redman CW, Sims C, Conrad KP. Expression of inflammatory cytokines in placentas from women with preeclampsia. J Clin Endocrinol Metab 2001; 86: 2505-12.
14. Hayashi M, Ueda Y, Yamaguchi T, et al. Tumor necrosis factoralpha in the placenta is not elevated in pre-eclamptic patients despite its elevation in peripheral blood. Am J Reprod Immunol 2005; 53: 113-9.
15. Witlin AG, Sibai BM. Magnesium sulfate therapy in preeclampsia and eclampsia. Obstet Gynecol 1998; 92: 883-9.
16. Lucas MJ, Leveno KJ, Cunningham FG. A comparison of magnesium sulfate with phenytoin for the prevention of eclampsia. N Engl J Med 1995; 333: 201-5.
17. Duley L, Henderson-Smart D. Magnesium sulphate versus phenytoin for eclampsia. Cochrane Database Syst Rev 2003; 4: CD000128.
18. Holcberg G, Sapir O, Hallak M, et al. Selective vasodilator effect of magnesium sulfate in human placenta. Am J Reprod Immunol 2004; 51: 192-7.
19. Roberts JM. Magnesium for preeclampsia and eclampsia. N Engl J Med 1995; 333: 250-1.
20. Doyle LW, Crowther CA, Middleton P, Marret S. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst Rev 2007; 3: CD004661.
21. Nelson KB, Grether JK. Can magnesium sulfate reduce the risk of cerebral palsy in very low birth weight infants? Pediatrics 1995; 95: 263-7.
22. Hauth JC, Goldenberg RL, Nelson KG, Rouse DJ. Reduction of cerebral palsy with maternal magnesium sulfate treatment in newborns weighing 500-1,000 G. Am J Obstet Gynecol 1995; 172: 419.
23. Espinoza MI, Parer JT. Mechanisms of asphyxial brain damage, and possible pharmacologic interventions, in the fetus. Am J Obstet Gynecol 1991; 164: 1582-9.
24. Dammann O, Leviton A. Maternal intrauterine infection, cytokines, and brain damage in the preterm newborn. Pediatr Res 1997; 42: 1-8.
25. Yoon BH, Jun JK, Romero R, et al. Amniotic fluid inflammatory cytokines (interleukin-6, interleukin-1beta tumor necrosis factoralpha), neonatal brain white matter lesions, and cerebral palsy. Am J Obstet Gynecol 1997; 177: 19-26.
26. Nelson KB, Dambrosia JM, Grether JK, Phillips TM. Neonatal cytokines and coagulation factors in children with cerebral palsy. Ann Neurol 1998; 44: 665-75.
27. Holcberg G, Amash A, Sapir O, et al. Different effects of magnesium sulfate and angiotensin II on the capacity of the fetal and maternal compartments of normal human placenta to secrete TNF-alpha and IL-6. J Reprod Immunol 2006; 69: 115-25.
28. Holcberg G, Amash A, Sapir O, et al. Perfusion with lipopolysaccharide differently affects the secretion of interleukin-1 beta and interleukin-1 receptor antagonist by term and preterm human placentae. Placenta 2008; 29: 593-601.
29. Peracoli JC, Rudge MV, Peracoli MT. Tumor necrosis factoralpha in gestation and puerperium of women with gestational hypertension and pre-eclampsia. Am J Reprod Immunol 2007; 57: 177-85.
30. Meekins JW, McLaughlin PJ, West DC, McFadyen IR, Johnson PM. Endothelial cell activation by tumour necrosis factor-alpha (TNF-alpha) and the development of pre-eclampsia. Clin Exp Immunol 1994; 98: 110-4.
31. Makhlouf MA, Simhan HN. Effect of tocolytics on interleukin-8 production by human amniotic and decidual cells. J Reprod Immunol 2006; 69: 1-7.
32. Bernardin D, Nasulewic A, Mazur A, Maier JA. Magnesium and microvascular endothelial cells: a role in inflammation and angiogenesis. Front Biosci 2005; 10: 1177-82.
33. Maier JA, Malpuech-Brugere C, Zimowska W, Rayssiguier Y, Mazur A. Low magnesium promotes endothelial cell dysfunction: implications for atherosclerosis, inflammation and thrombosis. Biochim Biophys Acta 2004; 1689: 13-21.
34. Nakagawa M, Oono H, Nishio A. Enhanced production of IL-1beta and IL-6 following endotoxin challenge in rats with dietary magnesium deficiency. J Vet Med Sci 2001; 63: 467-9.
35. Rochelson B, Dowling O, Schwartz N, Metz CN. Magnesium sulfate suppresses inflammatory responses by human umbilical vein endothelial cells (HuVECs) through the NFkappaB pathway. J Reprod Immunol 2007; 73: 101-7.